ResearchMoz

Hemophilia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Publisher Name » GlobalData
Published Date » 2011-09-12
No. Of Pages » 135

GlobalData, the industry analysis specialist, has released its new report, Hemophilia Therapeutics Pipeline Assessment and Market Forecasts to 2018. The report is an essential source of information and analysis on the global Hemophilia Therapeutics market. The report identifies the key trends shaping and driving the global Hemophilia Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Hemophilia Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Hemophilia Therapeutics market. Its scope includes 
  • Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Hemophilia Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017. 
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
  • Analysis of the current and future competition in the seven key countries Hemophilia Therapeutics market. 
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. 
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Hemophilia Therapeutics market.
  • Analysis of key recent licensing and partnership agreements in Hemophilia Therapeutics market 
Reasons to buy

The report will enhance your decision making capability. It will allow you to 
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. 
  • Develop business strategies by understanding the trends shaping and driving the global Hemophilia Therapeutics market. 
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Hemophilia Therapeutics market in future. 
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. 
  • Whats the next big thing in the global Hemophilia Therapeutics market landscape? Identify, understand and capitalize.
Table of content

1 Table of contents
1 Table of contents 3
1.1 List of Tables 6
1.2 List of Figures 7

2 Hemophilia Therapeutics - Introduction 9
2.1 Disease Overview 9
2.2 Classification of Hemophilia and Other Bleeding Disorders 10
2.2.1 Classification of Hemophilia on the Basis of Coagulation Factor Deficiency 10
2.2.2 Classification of Hemophilia on the Basis of Bleeding Manifestations 10
2.2.3 Other Bleeding Disorders 11
2.3 Epidemiology 11
2.4 Etiology 12
2.5 Sign and Symptoms 12
2.6 Diagnosis 13
2.7 Treatment and Management of Hemophilia 13
2.7.1 Factor Concentrates 13
2.7.2 Whole Blood 18
2.7.3 Fresh Plasma 18
2.7.4 Desmopressin (DDAVP) 18
2.7.5 Antifibrinolytic agents 18
2.7.6 Inhibitors 18
2.7.7 Gene Therapy 20
2.7.8 Advantages and Disadvantages of Treatment Methods of Hemophilia 21
2.8 Management of Hemophilia 22
2.9 Acquired Hemophilia 22
2.9.1 Treatment of Acquired Hemophilia 22
2.10 GlobalData Pipeline Report Guidance 23

3 Hemophilia Therapeutics - Market Characterization 24
3.1 Hemophilia Therapeutics Market Size (2005-2010) - Global 24
3.2 Hemophilia Therapeutics Market Forecast (2010-2018) Global 26
3.3 Hemophilia Therapeutics Market Size (2005-2010) - The US 29
3.4 Hemophilia Therapeutics Market Forecast (2010-2018) - The US 31
3.5 Hemophilia Therapeutics Market Size (2005-2010) - France 34
3.6 Hemophilia Therapeutics Market Forecast (2010-2018) - France 36
3.7 Hemophilia Therapeutics Market Size (2005-2010) - Germany 39
3.8 Hemophilia Therapeutics Market Forecast (2010-2018) - Germany 41
3.9 Hemophilia Therapeutics Market Size (2005-2010) - Italy 45
3.10 Hemophilia Therapeutics Market Forecast (2010-2018) - Italy 47
3.11 Hemophilia Therapeutics Market Size (2005-2010) - Spain 50
3.12 Hemophilia Therapeutics Market Forecast (2010-2018) - Spain 52
3.13 Hemophilia Therapeutics Market Size (2005-2010) - The UK 55
3.14 Hemophilia Therapeutics Market Forecast (2010-2018) - The UK 57
3.15 Hemophilia Therapeutics Market Size (2005-2010) - Japan 60
3.16 Hemophilia Therapeutics Market Forecast (2010-2018) - Japan 62
3.17 Drivers and Barriers for the Hemophilia Therapeutics Market 65
3.17.1 Drivers for the Hemophilia Therapeutics Market 65
3.17.2 Barriers for the Hemophilia Therapeutics Market 66
3.18 Opportunity and Unmet Need 66
3.18.1 Opportunity and Unmet Need for Hemophilia A 68
3.18.2 Opportunity and Unmet Need for Hemophilia B 69
3.18.3 Opportunity and Unmet Need for Hemophilia A and B Patients with Inhibitors 70
3.19 Key Takeaway 71

4 Hemophilia Therapeutics Market - Competitive Assessment 72
4.1 Hemophilia Therapeutics Market Overview 72
4.2 Strategic Competitor Assessment 74
4.2.1 Competitor Assessment Within Different Therapeutic Categories Employed in Hemophilia Treatment 74
4.3 Product Profile for the Major Marketed Products in the Hemophilia Therapeutics Market 77
4.3.1 NovoSeven (Coagulation Factor VIIa) 77
4.3.2 Advate (Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method) 78
4.3.3 Kogenate FS (Antihemophilic Factor (Recombinant) Formulated with Sucrose) 78
4.3.4 XYNTHA (Antihemophilic Factor (Recombinant), Plasma/Albumin-Free) 79
4.3.5 BeneFIX (Coagulation Factor IX (Recombinant)) 80
4.3.6 Monoclate-P (Antihemophilic factor (human) Factor VIII: C pasteurized monoclonal antibody purified) 80
4.3.7 Mononine (Coagulation factor IX (human)) 81
4.3.8 FEIBA-VH (Anti-Inhibitor Coagulant Complex) 82
4.4 Key Takeaway 82

5 Hemophilia Therapeutics - Pipeline Assessment 83
5.1 Overview 83
5.2 Strategic Pipeline Assessment 83
5.3 Hemophilia Pipeline Pipeline by Phases of Development 84
5.3.1 Hemophilia Therapeutics Pre-registration 84
5.3.2 Hemophilia Therapeutics Phase III Pipeline 85
5.3.3 Hemophilia Therapeutics Phase II Pipeline 86
5.3.4 Hemophilia Therapeutics Phase I/II Pipeline 86
5.3.5 Hemophilia Therapeutics Phase I Pipeline 87
5.3.6 Hemophilia Therapeutics Preclinical Pipeline 88
5.3.7 Hemophilia Therapeutics Discovery Pipeline 89
5.4 Hemophilia Therapeutics Pipeline by Mechanism of Action 90
5.5 Hemophilia Therapeutics Pipeline by Therapeutic Class 91
5.5.1 Technology Trends Analytic Framework 92
5.6 Hemophilia Therapeutics Promising Drugs under Clinical Development 93
5.7 Molecule Profile for Promising Drugs Under Clinical Development 94
5.7.1 NecLip-pdFVIII (LongAte) 94
5.7.2 Human-cl rhFVIII 94
5.7.3 NN7008 (recombinant factor VIII or rFVIII) 94
5.7.4 NN7999 (N9-GP, rFIX glycopegylated) 95
5.7.5 Kogenate PF (recombinant factor VIII, BAY81-8973) 96
5.7.6 Long Lasting rFactor VIII Fc Fusion Protein (rFVIIIFc) 97
5.7.7 Long Lasting rFactor IX Fc Fusion Protein (rFIXFc) 98
5.7.8 IB1001 (Recombinant Factor IX) 99
5.7.9 OBI-1 (rpFVIII) 99
5.7.10 BAX 326 100
5.7.11 FEIBA NF 100
5.7.12 Biostate 101
5.8 Key Takeaway 101

6 Hemophilia Therapeutics - Clinical Trials Mapping 102
6.1 Clinical Trials by Country (US, EU5 and Japan) 102
6.2 Clinical Trials by Phase 103
6.3 Clinical Trials by Status 104
6.4 Overall Sponsors 105
6.5 Prominent Sponsors 106
6.6 Top Companies Participating in Hemophilia Therapeutics Clinical Trials 107

7 Hemophilia Therapeutics - Strategic Assessment 108
7.1 Hemophilia Therapeutics: Implications for Future Market Competition 108

8 Hemophilia Therapeutics - Future Players 109
8.1 Introduction 109
8.2 Company Profiles 109
8.2.1 Baxter International Inc. 109
8.2.2 Recoly NV 111
8.2.3 Bayer AG 111
8.2.4 Novo Nordisk A/S 113
8.2.5 CSL Limited 114
8.2.6 Octapharma AG 115
8.2.7 Biogen Idec 117
8.2.8 Inspiration Biopharmaceuticals, Inc 118
8.2.9 Ipsen S.A. 119
8.2.10 Other Companies in the Hemophilia Therapeutics Market 120

9 Hemophilia Therapeutics - Licensing and Partnership Deals 124

10 Hemophilia Therapeutics - Appendix 129
10.1 Market Definitions 129
10.2 Abbreviations 129
10.3 Methodology 130
10.3.1 Coverage 130
10.3.2 Secondary Research 130
10.3.3 Forecasting 131
10.3.4 Primary Research 133
10.3.5 Expert Panel Validation 134
10.4 Contact Us 134
10.5 Disclaimer 134
10.6 Bibliography 134

List of Tables


Table 1: Bleeding Manifestations in Hemophilia 10
Table 2: Hemophilia, Patients Diagnosed in 2009 12
Table 3: Hematology Laboratory Tests 13
Table 4: Consumption Breakdown of Factor Concentrates 14
Table 5: Characteristics of Factor VIII Replacement Products 16
Table 6: Characteristics of Factor IX Replacement Products 17
Table 7: Characteristics of Bypassing Agents 19
Table 8: Hemophilia Therapeutics Market, Global, Revenue ($m), 20052010 26
Table 9: Hemophilia Therapeutics Market, Global, Forecast ($m), 20102018 28
Table 10: Hemophilia Therapeutics Market, The US, Revenue ($m), 20052010 31
Table 11: Hemophilia Therapeutics Market, The US, Forecast ($m), 20102018 33
Table 12: Hemophilia Therapeutics Market, France, Revenue ($m), 20052010 36
Table 13: Hemophilia Therapeutics Market, France, Forecast ($m), 20102018 38
Table 14: Hemophilia Therapeutics Market, Germany, Revenue ($m), 20052010 41
Table 15: Hemophilia Therapeutics Market, Germany, Forecast ($m), 20102018 44
Table 16: Hemophilia Therapeutics Market, Italy, Revenue ($m), 20052010 47
Table 17: Hemophilia Therapeutics Market, Italy, Forecast ($m), 20102018 49
Table 18: Hemophilia Therapeutics Market, Spain, Revenue ($m), 20052010 52
Table 19: Hemophilia Therapeutics Market, Spain, Forecast ($m), 20102018 54
Table 20: Hemophilia Therapeutics Market, The UK, Revenue ($m), 20052010 57
Table 21: Hemophilia Therapeutics Market, The UK, Forecast ($m), 20102018 60
Table 22: Hemophilia Therapeutics Market, Japan, Revenue ($m), 20052010 62
Table 23: Hemophilia Therapeutics Market, Japan, Forecast ($m), 20102018 64
Table 24: Major Brands - Usage in Hemophilia Therapeutics Market 72
Table 25: Approval and Launch Dates of Major Brands in Hemophilia Therapeutics Market 73
Table 26: Hemophilia Therapeutics Pre-registration, 2011 84
Table 27: Hemophilia Therapeutics Phase III Pipeline, 2011 85
Table 28: Hemophilia Therapeutics Phase II Pipeline, 2011 86
Table 29: Hemophilia Therapeutics Phase I/II Pipeline, 2011 86
Table 30: Hemophilia Therapeutics Phase I Pipeline, 2011 87
Table 31: Hemophilia Therapeutics Preclinical Pipeline, 2011 88
Table 32: Hemophilia Therapeutics Discovery Pipeline, 2011 89
Table 33: Mechanism of Action for the Other molecules in the Figure Above 90
Table 34: Hemophilia Therapeutics Promising Drugs Under Clinical Development, 2011 93
Table 35: Hemophilia Therapeutics Clinical Trials by Country, 2011 102
Table 36: Hemophilia Therapeutics Clinical Trials by Phase, 2011 103
Table 37: Hemophilia Therapeutics Clinical Trials by Status, 2011 104
Table 38: Hemophilia Therapeutics Overall Sponsors, 2011 105
Table 39: Hemophilia Therapeutics Prominent Sponsors, 2011 106
Table 40: Hemophilia Therapeutics: Top Companies Participating in Therapeutics Clinical Trials, 2011 107
Table 41: Baxter - Hemophilia Pipeline 2011 110
Table 42: Recoly NV - Hemophilia Pipeline 2011 111
Table 43: Bayer - Hemophilia pipeline 2011 112
Table 44: Novo Nordisk - Hemophilia Pipeline 2011 113
Table 45: CSL Limited - Hemophilia Pipeline 2011 115
Table 46: Octapharma AG - Hemophilia Pipeline 2011 116
Table 47: Biogen Idec. - Hemophilia Pipeline 2011 118
Table 48: Inspiration Biopharmaceuticals, Inc. - Hemophilia Pipeline 2011 118
Table 49: Ipsen SA - Hemophilia Pipeline 2011 120
Table 50: Hemophilia Therapeutics Market Other Future Players, 2011 120
Table 51: Hemophilia Therapeutics, Licensing and Partnership Deals, 2011 124

List of Figures


Figure 1: The Coagulation Cascade
Figure 2: Patients Diagnosed in 2009
Figure 3: Proportional Usage of Plasma Versus Recombinant Factor VIII for Hemophilia A Patients Reported in WFH Survey 2009
Figure 4: Proportional Usage of Plasma Versus Recombinant Factor IX for Hemophilia B Patients Reported in WFH Survey 2009
Figure 5: Advantages and Disadvantages of Treatment Methods of Hemophilia
Figure 6: Key Aspects of Management of Hemophilia
Figure 7: Hemophilia A Therapeutics Market, Global, Revenue ($m), 2005-2010
Figure 8: Hemophilia B Therapeutics Market, Global, Revenue ($m), 2005-2010
Figure 9: Hemophilia Therapeutics (A&B), Global, Market Share (%), 2010
Figure 10: Hemophilia A Therapeutics Market, Global, Forecasts ($m), 2010-2018
Figure 11: Hemophilia B Therapeutics Market, Global, Forecasts ($m), 2010-2018
Figure 12: Hemophilia Therapeutics (A&B), Global, Market Share (%), 2018
Figure 13: Hemophilia A Therapeutics Market, The US, Revenue ($m), 2005-2010
Figure 14: Hemophilia B Therapeutics Market, The US, Revenue ($m), 2005-2010
Figure 15: Hemophilia Therapeutics (A&B), The US, Market Share (%), 2010
Figure 16: Hemophilia A Therapeutics Market, The US, Forecasts ($m), 2010-2018
Figure 17: Hemophilia B Therapeutics Market, The US, Forecasts ($m), 2010-2018
Figure 18: Hemophilia Therapeutics (A&B), The US, Market Share (%), 2018
Figure 19: Hemophilia A Therapeutics Market, France, Forecast ($m), 2005-2010
Figure 20: Hemophilia B Therapeutics Market, France, Revenue ($m), 2005-2010
Figure 21: Hemophilia Therapeutics (A&B), France, Market Share (%), 2010
Figure 22: Hemophilia A Therapeutics Market, France, Forecast ($m), 2010-2018
Figure 23: Hemophilia B Therapeutics Market, France, Forecast ($m), 2010-2018
Figure 24: Hemophilia Therapeutics (A&B), France, Market Share (%), 2018
Figure 25: Hemophilia A Therapeutics Market, Germany, Revenue ($m), 2005-2010
Figure 26: Hemophilia B Therapeutics Market, Germany, Revenue ($m), 2005-2010
Figure 27: Hemophilia Therapeutics (A&B), Germany, Market Share (%), 2010
Figure 28: Hemophilia A Therapeutics Market, Germany, Forecast ($m), 2010-2018
Figure 29: Hemophilia B Therapeutics Market, Germany, Forecast ($m), 2010-2018
Figure 30: Hemophilia Therapeutics (A&B), Germany, Market Share (%), 2018
Figure 31: Hemophilia A Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 32: Hemophilia B Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 33: Hemophilia Therapeutics (A&B), Italy, Market Share (%), 2010
Figure 34: Hemophilia A Therapeutics Market, Italy, Forecast ($m), 2010-2018
Figure 35: Hemophilia A Therapeutics Market, Italy, Forecast ($m), 2010-2018
Figure 36: Hemophilia Therapeutics (A&B), Italy, Market Share (%), 2018
Figure 37: Hemophilia A Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 38: Hemophilia B Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 39: Hemophilia Therapeutics (A&B), Spain, Market Share (%), 2010
Figure 40: Hemophilia A Therapeutics Market, Spain, Forecast ($m), 2010-2018
Figure 41: Hemophilia B Therapeutics Market, Spain, Forecast ($m), 2010-2018
Figure 42: Hemophilia Therapeutics (A&B), Spain, Market Share (%), 2018
Figure 43: Hemophilia A Therapeutics Market, The UK, Revenue ($m), 2005-2010
Figure 44: Hemophilia B Therapeutics Market, The UK, Revenue ($m), 2005-2010
Figure 45: Hemophilia Therapeutics (A&B), The UK, Market Share (%), 2010
Figure 46: Hemophilia A Therapeutics Market, The UK, Forecast ($m), 2010-2018
Figure 47: Hemophilia B Therapeutics Market, The UK, Forecast ($m), 2010-2018
Figure 48: Hemophilia Therapeutics (A&B), The UK, Market Share (%), 2018
Figure 49: Hemophilia A Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 50: Hemophilia B Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 51: Hemophilia Therapeutics (A&B), Japan, Market Share (%), 2010
Figure 52: Hemophilia A Therapeutics Market, Japan, Forecast ($m), 2010-2018
Figure 53: Hemophilia B Therapeutics Market, Japan, Forecast ($m), 2010-2018
Figure 54: Hemophilia Therapeutics (A&B), Japan, Market Share (%), 2018
Figure 55: Hemophilia Market, Drivers and Barriers, 2011
Figure 56: Opportunity and Unmet Need for Hemophilia A Therapeutics Market, 2011
Figure 57: Opportunity and Unmet Need for Hemophilia B Therapeutics Market, 2011
Figure 58: Opportunity and Unmet Need for Hemophilia A&B Inhibitors Therapeutics Market, 2011
Figure 59: Hemophilia A Therapeutics - Strategic Competitor Assessment, 2011
Figure 60: Hemophilia B Therapeutics - Strategic Competitor Assessment, 2011
Figure 61: Hemophilia A and B with Inhibitors Therapeutics, 2011
Figure 62: Hemophilia Therapeutics - Pipeline by Phase of Development, 2011
Figure 63: Hemophilia Therapeutics - Clinical Pipeline by Mechanism Of Action, 2011
Figure 64: Hemophilia Therapeutics - Clinical Pipeline by Therapeutic Class, 2011
Figure 65: Hemophilia Therapeutics - Technology Trends Analytics Framework, 2011
Figure 66: Hemophilia Therapeutics - Technology Trends Analytics Framework - Description, 2011
Figure 67: Hemophilia Therapeutics - Clinical Trials by Country, 2011
Figure 68: Hemophilia Therapeutics - Clinical Trials by Phase, 2011
Figure 69: Hemophilia Therapeutics - Clinical Trials by Status, 2011
Figure 70: Hemophilia Therapeutics - Overall Sponsors, 2011
Figure 71: Hemophilia Therapeutics - Prominent Sponsors, 2011
Figure 72: Hemophilia Therapeutics - Top Companies Participating in Clinical Trials, 2011
Figure 73: Implications for Future Market Competition in Hemophilia Therapeutics Market, 2011
Figure 74: Hemophilia - Pipeline by Company, 2011
Figure 75: GlobalData Market Forecasting Model

Upcoming Reports:

Direct Methanol Fuel Cell Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
Direct methanol fuel cells provide extended run times with quick refill of charging liquid. These cells are expected to equal the cost with thin film batteries by the end of the forecasted period. Increasing demand for portable electricity with increasing use of broadband cell phones, laptops, and tablet PCs is mainly driving the DMFC market. Global market for direct methanol fuel cell (DMFC) is expected to reach 92,000 units by 2016 at an estimated growth rate of 45.3%. This tremendous growth in the DMFC market is expected as a result of the new generation of portable...
Bath And Shower Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
Product innovations and use of nature-based ingredients in bath and shower products is driving the growth of this market. Consumers are focusing on buying nature-based products rather than chemical-based products. Many new manufacturers are emerging in the bath and shower industry as this market is creating new growth opportunities with new products development, packaging innovations, lifestyle influences, and distribution or pricing issues. The skin care market is posing the biggest challenge to the growth of the bath and shower industry as this industry is catching consumer...
Plastic Polymers Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018
By - Transparency Market Research
The research and development over the plastic material led to the invention of Polymer Plastics which is a long chain of different but similar categorical molecules or a combination of many units.  The plastic polymers are of the following two types: Thermoplastic polymers Thermoset polymers The thermoplastic polymers can be heated and reheated again and again possessing  a unique capability which is quite useful in manufacturing new articles or components of different products.  The invention of plastic created a new...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Select License type:

Share this report

Related News

One-third of Massachusetts Hospitals Facing Financial Downturn
Sep 14, 2012  
The healthcare Industry in the United States works as a separate entity and many of the healthcare services are privately owned and operated. Healthcare has always been a topic of debate for the U.S. government because policy makers argue that the system is not delivering value for money services. In fact government is spending twice as much on life expectancy and infant mortality rate...
Now At-Home TB Diagnosis Looks Possible
Sep 14, 2012  
According to a recent research published in Nature Chemistry, scientists have revealed that a certain sensitive fluorescent molecule is capable of efficiently and quickly tracing TB (tuberculosis) bacteria from the sputum samples. The year 2010 registered approximately 4000 deaths per day because of TB. TB diagnosis takes a few weeks and the disease being contagious puts others at...
China Economy Gets USD 157 Billion Stimulus with Sanction for 60 Infrastructure Projects
Sep 14, 2012  
Seen as a much required economical stimulus to revive the economy stuck in the worst slowdown in the past three years, China has approved 60 different infrastructure projects valued at more than USD 150 billion. Immediately after the official confirmation of the decision, stocks of major industries such as cement and steel have seen a rise on hopes generated by plans to build ports, highways,...
Battling against flu, vaccination necessary for health workers
Sep 14, 2012  
To battle against flu this season, health officials have tightened their resolve to get more health care workers vaccinated. Flu is a disease that transfers from one to another. Keeping this in mind health officials want every worker in the health care department to get vaccinated. By doing this, it will lessen the chances of others getting affected by this disease. Health officials...
Japan to Cut Import Duties on Indian Generic Drugs Imports
Sep 14, 2012  
The 44th ASEAN Economic Ministers Meeting held last week in Cambodia has certainly brought good news for the Indian Pharmaceuticals industry. During the meeting on the sidelines of the 44th ASEAN Economic Ministers Meet, Indian Commerce and Industry Minister Anand Sharma brought up the issue with his Japanese counterpart Yukio Edano. Yukio Edano is the minister of economy, trade and Industry...